The Fetal Safety of Hydrocortisone-Pramoxine (Proctofoam-HC) for the Treatment of Hemorrhoids in Late Pregnancy

Neda Ebrahimi, Sabina Vohra, Christelle Gedeon, Hani Akoury, Paul Bernstein, Nicholas Pairaudeau, Johanne Cormier, Lorraine Dontigny, Marc Yvon Arsenault, Claude Fortin, Martine Goyet, Chantal Lafortune, Johanne Lalande, Coralie Beauchamp, Francis Engel, Anne Fortin, Anna Taddio, Tom Einarson, Gideon Koren

פרסום מחקרי: פרסום בכתב עתמאמרביקורת עמיתים

20 ציטוטים ‏(Scopus)

תקציר

Objective: Fetal safety has never been studied for any drug used in the treatment of hemorrhoids. Proctofoam-HC is a combination of a corticosteroid and a local anaesthetic that is proven effective for the treatment of hemorrhoids. The objective of this study was to assess prospectively the fetal safety of third trimester exposure to Proctofoam-HC. Methods: In a multicentre study, 240 women exposed to Proctofoam-HC in the third trimester and a similar number of control pregnant women were followed up postnatally. Results: When compared to controls exposure to Proctofoam-HC was not associated with any adverse fetal effects on birth weight, gestational age, rates of prematurity, or pre- or postnatal complications. Conclusion: Proctofoam-HC is safe to use in the treatment of hemorrhoids in late pregnancy.

שפה מקוריתאנגלית
עמודים (מ-עד)153-158
מספר עמודים6
כתב עתJournal of Obstetrics and Gynaecology Canada
כרך33
מספר גיליון2
מזהי עצם דיגיטלי (DOIs)
סטטוס פרסוםפורסם - 2011
פורסם באופן חיצוניכן

טביעת אצבע

להלן מוצגים תחומי המחקר של הפרסום 'The Fetal Safety of Hydrocortisone-Pramoxine (Proctofoam-HC) for the Treatment of Hemorrhoids in Late Pregnancy'. יחד הם יוצרים טביעת אצבע ייחודית.

פורמט ציטוט ביבליוגרפי